ESPR Q1 2022 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

Q1 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$19M+136.1% YoY

Gross Profit

$12M62.2% margin

Operating Income

-$43M-228.2% margin

Net Income

-$57M-301.2% margin

EPS (Diluted)

$-1.16

QoQ Revenue Growth

+22.3%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$39M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$343M

Total Liabilities

$592M

Stockholders' Equity

-$249M

Cash & Equivalents

$150M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$8M	+136.1%
Gross Profit	$12M	$6M	+89.1%
Operating Income	-$43M	-$83M	+48.1%
Net Income	-$57M	-$91M	+37.6%

Revenue Segments

Collaboration Revenue

$5M51%

Royalty Revenue And Product Sales Bulk Tablets

$5M49%